

Ref. No.P-66/2025-26/45  
September 26, 2025

The Relationship Manager,  
Department of Corporate Relations  
BSE Ltd,  
P.J. Towers, Dalal Street  
Fort, MUMBAI – 400 001

**SUBJECT: SUMMARY OF PROCEEDINGS OF THE 53rd ANNUAL GENERAL MEETING ('AGM') OF THE COMPANY HELD ON FRIDAY, 26<sup>TH</sup> SEPTEMBER, 2025**

Dear Sir,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform that the following businesses were transacted at the 53<sup>rd</sup> Annual General Meeting ("AGM") of members of 3B BlackBio Dx Limited (Formerly, Kilpest India Limited) ("Company") held today i.e. Friday, 26<sup>th</sup> September, 2025 through Video Conferencing (VC) / Other Audio Visual Means (OAVM) started at 11:30 A.M. and concluded at 12:08 P.M.

Mr. Dharendra Dubey, Chairman and Managing Director, chaired the Meeting.

The requisite quorum being present, the Chairman called the Meeting to order. The Chairman addressed the members. A copy of the Investor's Presentation presented at the Annual General Meeting ('AGM') held today is attached herewith.

In compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and Regulation 44 of the SEBI Listing Regulations, the Company had provided to its members the remote e-voting facility to exercise their right to vote in respect of the resolutions proposed at the AGM, convened vide Notice dated 14<sup>th</sup> August, 2025, through e-voting platform hosted by Central Depository Services (India) Limited (CDSL) from Tuesday, 23<sup>rd</sup> September, 2025 (9:00 a.m. IST onwards) to Thursday, 25<sup>th</sup> September, 2025 (5:00 p.m. IST). Members, who could not cast their votes through remote e-voting before the Meeting, but attended the AGM, were also provided with the facility of remote e-Voting during the AGM by CDSL.

**Ordinary Business**

1. Adoption of Audited Standalone Financial Statements of the Company for the financial year ended 31<sup>st</sup> March 2025, the reports of the Board of Directors and Auditors.
2. Adoption of Audited Consolidated Financial Statements of the Company for the financial year ended 31<sup>st</sup> March 2025 along with the Auditors report.
3. Declaration of dividend at the rate of Rs. 4.00/- (Rupees Four only) per share on equity shares for the year ended 31<sup>st</sup> March 2025.

**Special Business**

4. Appointment of a Director in place of Mrs. Mithla Dubey (DIN: 03597415) who retires by rotation and being eligible, offers herself for re-appointment.

5. Appointment of Mr. Praveen Kumar Rai , Practicing Company Secretary, as the Secretarial Auditor of the company for five consecutive years i.e. for FY 2025-26 to FY 2029-30.
6. Ratification of Remuneration of the Cost Auditor.
7. Revision in remuneration (commission and salary) of Mr. Nikhil Kuber Dubey, (DIN: 00538049), Whole-Time Director cum Chief Financial Officer of the company.
8. Revision in remuneration (commission and salary) of Mr. Dhirendra Dubey, (DIN: 01493040), Chairman cum Managing Director of the company
9. Re-appointment of Mr. Dhirendra Dubey (DIN: 01493040) as Chairman-cum-Managing Director of the Company for five years w.e.f. 30<sup>th</sup> November, 2025 to 29<sup>th</sup> November, 2030.
10. Appointment/Regularization of Mr. Vivek Saihgal (DIN: 11228713) as an Independent Director of the Company for a term of five (5) years w.e.f. 14<sup>th</sup> August, 2025 to 13<sup>th</sup> August, 2030.

The above businesses were transacted through remote e-voting and e-voting at the Annual General Meeting as required under the Companies Act, 2013 and SEBI Listing Regulations.

Mr. Praveen Kumar Rai, Proprietor of M/s. P.K. Rai & Associates, Practicing Company Secretary, was appointed as the scrutinizer to scrutinize the remote e-voting process and e-voting process at the Annual General Meeting.

Details of voting results under Regulation 44(3) of SEBI Listing Regulations will be displayed on Company's website and shall be submitted separately to the Stock Exchanges along with Scrutinizer's Report.

Thanking you,

This is for your information and records.

Yours faithfully,  
For 3B BlackBio DX Limited (Formerly, KILPEST INDIA LTD)

**Navneet Kaur** Digitally signed by Navneet Kaur  
Date: 2025.09.26 14:29:58 +05'30'

Navneet Kaur  
Company Secretary  
ACS No.: 29130  
Encls: as above



**3B BlackBio Dx Ltd.**

An ISO 13485:2016 Certified Company

Dear Shareholders,

It gives me great pleasure to welcome you all to the 53<sup>rd</sup> Annual General Meeting of 3B BlackBio Dx Limited. Today, we come together not only to review the financial outcomes of the fiscal year 2024–25 but also to reflect on the milestones and successes we have achieved as a collective.

At the outset, I would like to express my sincere appreciation to each one of you for your continued trust and confidence in our journey. The amalgamation of our company with its subsidiary and the acquisition of Coris BioConcept, Belgium have marked pivotal chapters, strengthening our foundation and reaffirming our position as a trusted leader in molecular diagnostics within the healthcare sector.

For more than fifty years, 3B BlackBio Dx Limited has stood as a testament to resilience and innovation, continually delivering high-quality solutions to patients, clinicians, and partners. This legacy has been possible only because of the relentless commitment of our employees, the enduring loyalty of our customers, and the steadfast support of you—our esteemed shareholders. We remain grateful for your unwavering partnership throughout these decades.

With this spirit, let us now turn our attention to an overview of the company's financial performance (consolidated) for the year ended 31<sup>st</sup> March 2025.

- Revenue from operations - ₹ 96.47 Crores / ₹ 964.69 Million • Profit before tax - ₹ 63.99 Crores / ₹ 639.98 Million
- Profit after tax - ₹ 47.69 Crores / ₹ 476.91 Million • Earnings per share - ₹ 55.66

These results reflect not only our robust operational strategies but also the strength of our brand in a competitive market. The detailed accounts for the year, along with the Directors' and Auditors' Reports, have already been circulated to you. With your permission, I would like to take them as read.





**3B BlackBio Dx Ltd.**

An ISO 13485:2016 Certified Company

**Disclaimer:**

***This presentation may contain some of the forward-looking statements which are completely based on the management's belief, opinion, and expectations as of today. These statements are not a guarantee of company's future performance and involve unforeseen risk and uncertainties.***





## India Business

In India, the company operates through three primary sales models:

- a) Tender Sales:** This accounts for approximately 5%-7% of the total sales and it depends on type of tender, etc.
- b) Reagent Rental Model:** In this model, we provide molecular diagnostic equipment to the labs / hospitals with a condition that only our assays are used, these are long-term contracts (typically signed for a duration of a minimum of 3 years) which are projected to contribute business of 20%-25% for this financial year and coming years. Currently we have over 15 contracts in place.
- c) Other Supplies:** Apart from above, we sell products to hospitals and labs which comprises the remaining 65%-70% of the total sales.

The customer base is split between labs and hospitals where ~65% of the business coming from labs and ~35% coming from hospitals. These models enable us to effectively meet diverse customer needs while driving our sales growth.

As we have mentioned in our quarterly presentations, the Total Addressable Market (TAM) for Molecular Diagnostics (MDx) in India is estimated at approx. ₹350-450 Cr and we hold a 12%-15% market share, positioning ourselves among the market leaders. The MDx industry in India is projected to grow at 8%-10% CAGR over the next few years due to factors like increasing adoption of molecular diagnostics across diagnostic labs and hospitals and government projects. However, this growth is attracting increased competition. Even with this, we are hoping to grow at 15%-20% for FY 2025-26, backed by our extensive product portfolio and strong market presence over the years and high-quality products well accepted by the customers.



**3B BlackBio Dx Ltd.**

An ISO 13485:2016 Certified Company

## Exports

TRUPCR® assays have garnered widespread acceptance globally with presence now in over 70 countries spanning across Europe, Middle East, APAC, LATAM, and North America (including the United States and Canada). We are now expanding ourselves in Africa as well which has always been a price competitive market.

We are now increasing our penetration in the existing markets by adding more customers, appointing distributors, and participating in international tenders, both independently and through distributors. Our continuous efforts to engage more international distributors have led to an increased acceptance of our products in new markets, expanding our footprint from 25 countries in 2021 to over 70 countries now. We are steadily entering newer markets by adding international distributors, and the results of these efforts will be visible in the coming years.

The export sales for FY 2024-25 were ₹ 171.04 Million compared to ₹ 86.89 Million in FY 2023-24. Due to confidentiality reasons we are not giving a geographical split of the sales, other than EU & UK. EU and UK sales numbers are disclosed by way of sales from the UK Subsidiary.

Maintaining this momentum, we are well-positioned to further expand our international business. With a targeted growth projection of 20-25%, it's evident that we are poised for continued success in the global market.

However collectively, we will grow at 15-20%\* including domestic sales in the FY 2025-26.

***\*This growth rate is subject to seasonal spikes of infectious diseases like Vector Borne and Flu which showed an unprecedented increase in the Q2 and Q3 of 2024-25.***





**3B BlackBio Dx Ltd.**

An ISO 13485:2016 Certified Company

## **UK Subsidiary – TRUPCR® Europe Limited**

TRUPCR® Europe completed a milestone of crossing £1.00 Million 2024-25 with sales of £1.28 Million compared to £0.66 Million in 2023-24.

Our UK subsidiary has emerged as a key growth driver, gaining strong traction across Europe with its “Made in UK” product range. The Manchester facility—equipped with sales, marketing, technical support, and R&D—has enabled efficient service delivery and market responsiveness. EU branding, coupled with improved logistics, has also supported successful expansion into LATAM and African markets via TPE.

The site’s ISO 13485:2016 certification by BSI, UK reinforces our commitment to quality and regulatory compliance, enhancing market access and customer confidence. With a revenue growth of over 90% in FY 2024–25, our UK operations are a clear testament to the success of our strategic investments. We project continued strong growth of 20–25% in the current fiscal year from TPE, positioning the UK subsidiary as a critical part of our international business expansion.





**3B BlackBio Dx Ltd.**

An ISO 13485:2016 Certified Company

## Acquisition of 100% Stake in Coris Holding SRL, Belgium

Your company—3B (70%) along with its UK subsidiary—TPE (30%) is pleased to announce that we have acquired all the shares of Coris Holding SRL, the parent company of Coris Bioconcept SRL (“Coris”) from Avacta Group Plc, London. Coris is a 30 years old manufacturer of Rapid Diagnostic Solutions for an upfront cash consideration of £2.15 Million (including net cash & customary working capital adjustments) with an earn-out based on future business performance of up to £0.615 Million payable (the “Acquisition”) totaling to £2.765 Million. The completion of purchase took place on 29<sup>th</sup> August 2025.

According to the latest unaudited financial results shared by Coris, the company reported unaudited revenue of €5.22 Million for the financial year ended 31<sup>st</sup> December 2024 (“FY24”). Coris achieved a gross margin of approximately 58.7%, however, recorded a negative EBITDA of €0.215 Million. Its’ net assets stood at €4.14 Million. Now, With efforts to launch new products, enter new territories and introduce better cost management, we expect to be EBITDA positive in FY 2026-27 as these efforts will take some time to materialize.

Coris’ product portfolio comprises rapid diagnostics *in vitro* diagnostic test kits, primarily focused on the antibiotic resistance markers (AMR). As part of this portfolio, the company offers a range of rapid lateral flow tests (LFT) designed to support early & accurate diagnosis at the point of care. Coris also offers an LFT ‘HAT Sero K-SeT’ for detecting antibodies specific to Trypanosoma brucei gambiense (a parasite that causes African sleeping sickness), a product that holds global monopoly.

Acquisition of Coris BioConcept SRL is a strategically thought move that strengthens our position in the IVD segment and our fight against AMR. The product portfolio of Coris complements our existing molecular diagnostics product range.

By combining our expertise in the PCR-based solutions and with Coris’ innovation in rapid testing, the company is accelerating its vision of faster, accessible, and more accurate diagnostics worldwide.





**3B BlackBio Dx Ltd.**

An ISO 13485:2016 Certified Company

## What Sets us Apart!

- Largest CE-IVD and Indian IVD Product Range with over 120 PCR assays developed and commercially available
- Highly experienced, strong and well retained team including Ph.Ds., MScs., MBAs in our Production, R&D, QC and Sales & Marketing.
- Only Indian molecular diagnostics company to have a subsidiary in UK and Belgium (now with the acquisition of Coris), establishing our credibility globally.
- All the sites – India, UK and Belgoum, are ISO 13485 certified by BSI, UK defining the strong Quality Management System the company follows.
- We deliver orders in the shortest TAT (Turn-Around-Time) in the industry.
- Technical support in the same time zone available to the end-users both for India and EU customers giving us an added advantage over competition.
- Only molecular company globally to integrate offerings for Rapid Diagnostics (Lateral Flow) & NGS solutions and covering the entire range of molecular diagnostic solutions in its true sense

The effective growth in the MDx business for FY Q1 2025-26 compared with Q1 2024-25 was ~18% which is well in line with the expected growth rate of 15-20%.





**3B BlackBio Dx Ltd.**

An ISO 13485:2016 Certified Company

## **Mergers & Acquisitions**

We have a focused M&A Strategy for which Coris BioConcept was the first acquisition that has been successfully completed after a long search and a year of negotiations. We will continue to look for more such opportunities in the IVD industry – both manufacturers and distributors which will have future growth potential and complement our existing product lines.

We will also be deploying some funds in the joint venture created in Manchester, UK depending on the need.

## **Dividend**

The Board of Directors of the Company are pleased to recommend a final dividend of ₹ 4.00 i.e., per equity share of face value of ₹ 10.00 each for the FY 2024-25.





**3B BlackBio Dx Ltd.**

An ISO 13485:2016 Certified Company

I would like to invite all Members present at the Meeting who have not yet cast their votes via remote e-voting, and who are eligible to do so, to participate in the e-voting process now. Voting will remain open for 15 minutes following the conclusion of the Meeting.

The Scrutinizer will provide a report after completing the scrutiny of both the votes cast during the AGM and those submitted via remote e-voting.

As we conclude, I extend my heartfelt gratitude to all our valued customers, both domestic and international, for their unwavering support. A special thanks goes to our supply and trade partners for ensuring the timely availability of our products. We also appreciate the continuous support from the Government of India, the Ministry of Health, and the Government of Madhya Pradesh for their collaboration with our initiatives.

Lastly, I would like to thank all our stakeholders. Your support is vital in helping us build a self-sufficient company and in achieving the vision of 'AatmaNirbhar Bharat' set forth by our Hon'ble Prime Minister.

**JAI HIND**





**3B BlackBio Dx Ltd.**  
An ISO 13485:2016 Certified Company

Now, we request the 2 registered speakers to ask 3 questions each.

